^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    TmPSMA-02

    i
    Associations

    News

    Trials
    Company:
    Gilead
    Drug class:
    PSMA-targeted CAR-T immunotherapy
    Related drugs:
    Associations

    News

    Trials
    1year
    TmPSMA-02 in mCRPC (clinicaltrials.gov)
    P1, N=18, Recruiting, University of Pennsylvania | Not yet recruiting --> Recruiting
    Enrollment open
    |
    TmPSMA-02
    2years
    A Study of TmPSMA-02 Chimeric Antigen Receptor (CAR) T-cells in Patients With Metastatic Castration Resistant Prostate Cancer (mCRPC) (clinicaltrials.gov)
    P1/2, N=114, Active, not recruiting, Tmunity Therapeutics | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    CAST (Calpastatin)
    |
    TmPSMA-02
    over2years
    A Study of TmPSMA-02 Chimeric Antigen Receptor (CAR) T-cells in Patients With Metastatic Castration Resistant Prostate Cancer (mCRPC) (clinicaltrials.gov)
    P1/2, N=114, Recruiting, Tmunity Therapeutics | Not yet recruiting --> Recruiting
    Enrollment open • Metastases
    |
    CAST (Calpastatin)
    |
    TmPSMA-02